Roger Estrada Tejedor

Roger Estrada Tejedor is an Associate Professor and Head of the GQF – Pharmaceutical Chemistry Group at the Department of Organic and Pharmaceutical Chemistry, IQS School of Engineering, Ramon Llull University. His work bridges computational chemistry, drug design, and medicinal applications, with a focus on cancer and rare diseases.

• PhD in Chemistry, Ramon Llull University (2011)
• Master’s in Applied Statistics, UNED (2013)
• Chemical Engineering Degree, IQS (2006)
• Chemistry Degree, IQS, Ramon Llull University (2004)

His research interests center on computational drug design, particularly using artificial intelligence and molecular modeling to develop novel therapeutics. Key areas include targeting pathogenic RNA, designing dual kinase inhibitors for pancreatic cancer, and developing degraders for B-cell lymphoma. His team explores innovative approaches such as allosteric inhibition, PROTACs, and antimalarial analogs.

The recent publication trends show a strong emphasis on targeted cancer therapies, RNA-interacting small molecules, and computational screening. His work spans from hit discovery to preclinical evaluation, often involving multi-target inhibitors and novel synthetic routes. The integration of cheminformatics and AI-driven design is a consistent theme across his publications.

Notable scientific contributions include projects such as DisX4lymph, ANTIMIR, and PreClinIQS080, supported by grants from MINECO, AGAUR, and the European Commission. While no specific awards are listed, his sustained research output and leadership reflect high scholarly impact.

Roger Estrada Tejedor advises students in the PhD in Chemistry and Chemical Engineering and contributes to the Master’s in Pharmaceutical Chemistry. He leads a multidisciplinary research team within the GQF group, fostering collaboration across Spain and France, particularly in hematological cancers. His lab is active in both academic and industrial translational research.